natgillin/translations-raw huggingface dataset:
hydrogen, ii) alkyl optionally substituted with a group selected from the group consisting of halogen, monoalkylamino, dialkylamino, monoalkylaminocarbonyl, dialkylaminocarbonyl, a saturated cyclic aminocarbonyl, alkoxy, alkoxyalkoxy and alkylcarbonyloxy, 
vodik, ii) alkil, izborno supstituiran sa skupinom koju se bira iz skupine koju čine halogen, monoalkilamino, dialkilamino, monoalkilaminokarbonil, dialkilaminokarbonil, zasićeni ciklički aminokarbonil, alkoksi, alkoksialkoksi i alkilkarboniloksi, iii) cikloalkil, izborno supstituiran s alkilom, izborno supstituiranim s jednim do tri halogena, iv) alkoksi,
wherein W represents an oxygen atom or CRcRd, wherein 
W predstavlja atom kisika ili CR"R", gdje
A method according to clause 4 wherein R6 is trifluoromethyl. 
Postupak sukladno zahtjevu 9, naznačen time, što Rs je trifluorometil.
A combination according to claim 4 wherein the PDE4 inhibitor is cilomilast. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je kortikosteroid mometazon furoat.
The number, distance and average speed of ambulatory movements were measured. 
Mjereni su broj, udaljenost 1 prosječna brzina ambulantnih pokreta.
one of components (A) and (B) as defined in Claim 3; together with 
(1) jednu od komponenti (A) 1 (B) kao što je definirano u patentnom zahtjevu 3, zajedno sa
describe the development of triple 5-HT, NE and DA re-uptake inhibitors for treatment of depression. 
opisuju razvoj trostrukog 5-HT, NE i DA inhibitura re-apsorpcije kod liječenja depresije (2003, Scorganic & Medical Chemistry Letters.
It is an object of the present invention to provide an engineered fuel feed stock, comprising at least one component derived from processed MSW waste stream and at least one sorbent. 
Modificirano zamjensko gorivo, koje sadržava najmanje jednu komponentu koja je dobivena iz procesiranog komunalnog otpada, a sirovina sadržava:
An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites capable of specifically binding one or more antigen targets, wherein two polypeptide chains have a structure represented by the formula: 
HR P20161030 T1 Protutijelu sličan vezivni protein koji sadrži četiri polipeptidna lanca koji tvore četiri mjesta vezanja antigena, pri čemu dva polipeptidna lanca imaju strukturu predstavljenu s formulom:
A method of treating cancer in a subject in need thereof, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the œsophagus and liver, lymphoblastic leukaemias, non-Hodgkin lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer, comprising administration of a compound of formula (I): wherein: 
Spoj formule (I) prema jednom od patentnih zahtjeva 1 do 5 ili adicijske soli istih s farmaceutski prihvatljivom kiselinom ili lužinom, naznačen time, da se koristi u liječenju karcinoma mokraćnog mjehura, mozga, dojke i maternice, kronične limfoidne leukemije, karcinoma debelog crijeva, karcinoma jednjaka i jetre, limfoblastične leukemije, ne-Hodgkinovog limfoma, melanoma, maligne hemopatije, mijeloma, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate i karcinoma pluća malih stanica.
For example, cancer in which PI3K activity contributes to its pathology and/or symptomatology include breast cancer, colon cancer, rectal cancer, endometrial cancer, gastric carcinoma, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or thyroid carcinoma 
Spoj, ili njegov pojedinačni stereoizomer ili smjesa stereoizomera, prema patentnom zahtjevu 50, naznačen time što je kancer - kancer dojke, kancer debelog crijeva, kancer rektuma, kancer endometrija, karcinom želudca, glioblastom, hepatostanični karcinom, sitnostanični kancer pluća, nesitnostanični kancer pluća, melanom, kancer jajnika, kancer grlića materice, kancer pankreasa, karcinom prostate, akutna mijelogena leukemija (AML), kronična mijelogena leukemija (CML) ili karcinom tireoidee.
-C(O)-heterocyclyl, wherein the heterocyclyl is selected from morpholin-4-yl, pyrrolidin-1-yl and piperidin-1-yl, optionally substituted with one or two groups selected from-F and-OH; and R3 is H, or C1-3alkyl optionally substituted with -OH; 
C(O)-heterociklil, gdje je heterociklil odabran od morfolin-4-ila, pirolidin-1-ila i piperidin-1-ila, opcionalno supstituiranih s jednom ili dvije skupine odabrane od –F i –OH; i je H, ili C1-3alkil opcionalno supstituiran s -OH;
correlating the presence or absence of the immunologic complex with the presence or absence of amyloid protein in the sample or specific body part or area of the subject; and 
(d) koreliranja prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku; i
Heating the pressurized feed material to a predetermined process temperature of 370 to 500° C.; 
– grijanju stlačenog dovodnog materijala do zadane temperature postupka od najmanje 370 stupnjeva;
The solution was cooled to 30 °C, filtered through a 1 µm filtration cartridge and cooled to 20-25 °C. 1.05 1 of conc. hydrochloric acid were added at 25-30 °C with measuring the pH (3.2 ± 0.2). 
Otopina je bila ohlađena na 30 "C, filtrirana kroz 1 um filtracijski uložak 1 ohlađena na 20-25 *C. U smjesu je pri temperaturi od 25-30 *C uz mjerenje pH (3,2 + 0,2) dodano 1,05 L koncentrirane klorovodične kiseline.
In some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is H; and R4 and R5 are H. In some embodiments, R1 is H or CH3; R2 is H or CH3; R3 is H; and one of R4 and R5 is H, and the other is —CH2—X, wherein X is phenyl or heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C1-C3 alkyl), O, and S; each optionally substituted with from 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, and —N(R′)R′. 
Ri je H ili CH;; R2 je H ili CHs; Rs je H; 1 R41 Rs su H; Ri je H ili CHs; R> je H ili CH3; Rs je H; i jedan od Ry i Rs je H, i drugi je -CH>-X, pri čemu X je fenil ili heteroaril uključujući od 5 do 6 atoma prstena pri čemu su 1, 2, ili 3 od atoma prstena neovisno odabrani od skupine koja se sastoji od N, NH, N(C;-C: alkila), O 1 S; pri čemu je svaki fenil ili heteroaril izborno supstituiran s od 1-3 supstituenata neovisno odabranih od skupine koja se sastoji od halogena, cijano, C;- Ce alkila, hidroksila, Cy-Cg alkoksi i -N(R')R';
containing 1 to 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur among the atoms of the ring, optionally containing 1 to 2 double bonds in the ring, optionally containing 1 to 3 carbonyl, sulfinyl, or sulfonyl groups in the ring, wherein the group is limited to a group having nitrogen as a ring constituent atom and the nitrogen having a bonding hand, or a group represented by the formula -NR11aR11b, wherein R11a and R11b may be the same or different and each represents hydrogen, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-10 cycloalkyl representing a mono- or bicyclic saturated aliphatic hydrocarbon group with 3 to 10 carbon atoms, C6-10 aryl, 5- to 10-membered heteroaryl or a 4- to 10-membered non-aromatic heterocyclic group representing 
(3) sadrži 1 do 2 heteroatoma odabrana iz skupine koja sadrži dušik, kisik 1 sumpor između atoma u prstenu, (4) proizvoljno sadrži 1 do 2 dvostruke veze u prstenu, (5) proizvoljno sadrži 1 do 3 karbonilne, sulfinilne, ili sulfonilne skupine u prstenu, pri čemu je skupina ograničena na skupinu koja ima dušik kao sastavni atom u prstenu 1 dušik koji ima valenciju za vezanje, ili skupinu prikazanu sa formulom -NR'"R!', pri čemu R!'* i R'" mogu biti isti ili različiti i svaki predstavlja vodik, C;.4 alkil, C34 alkenil, C34 alkinil, C3_19 cikloalkil koji predstavlja mono- ili bicikličku zasićenu alifatsku skupinu ugljikovodika sa 3 do 10 atoma ugljika, C4.yo aril, 5- do 10-člani heteroaril ili 4- do 10-članu ne-aromatsku heterocikličnu skupinu koja
The fruit and/or vegetable preparation according to claim 1, comprising at least 20% (w/w) fruit and/or vegetable material, preferably at least 30% (w/w) fruit and/or vegetable material, and even more preferably at least 40% (w/w) fruit and/or vegetable material, such as at least 50% (w/w) fruit and/or vegetable material. 
– prah, ili – vodena suspenzija. Visokoproteinski napitak s voćnom aromom u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je težinski omjer ukupni protein:sadržaj pepela u pripravku denaturiranog proteina sirutke najmanje 15, po mogućnosti najmanje 20, a još poželjnije najmanje 30, primjerice najmanje 40 ili najmanje 50.
secondary phases 0 to 30% by weight, preferably 3 to 20% by weight, and still more preferably 5 to 10% by weight relative to the total amount of clinker/cement, with the proportions of the phases amounting to 100%. 
* sekundarne faze 0 do 30 % mase, pri čemu proporcije faza klinkera iznose ukupno do 100 %, i mljeveni kalcijev sulfoaluminat klinker.
In another preferred embodiment, said nitrogen content is at least 0.1%, more preferably at least 0.2% by weight of dry matter. 
U još jednom poželjnom ostvarenju, spomenuti sadržaj dušika je najmanje 0,1%, poželjnije najmanje 0,2% po masi suhe tvari.
drying the obtained precipitate at a temperature ranging from room temperature to 40° C. under a pressure comprised between ambient pressure and under vacuum, for a duration of time ranging from 5 minutes to 1 day, wherein before drying, the precipitate is optionally washed with apolar solvent and thereafter lyophilized. 
– sušenja dobivenog taloga na temperaturi u rasponu od sobne temperature do 40 °C pod tlakom koji se kreće između tlaka okoliša i vakuuma, u trajanju u rasponu od 5 minuta do 1 dan, gdje se talog prije sušenja može isprati nepolarnim otapalom.
METHOD FOR PREPARING A TUBULAR MANUFACTURE SUCH AS A HOSIERY ITEM OR THE LIKE FOR AUTOMATED PICK-UP AT THE END OF ITS FORMATION ON A DOUBLE-CYLINDER CIRCULAR MACHINE WITH AT LEAST ONE FEED OR DROP AND DOUBLE-CYLINDER CIRCULAR MACHINE FOR PERFORMING THE METHOD 
Postupak za pripremu izrade cjevastih artikala poput čarapa ili sličnih artikala za automatsko podizanje na kraju njihovog oblikovanja na kružnom stroju s dvostrukim cilindrom (1) s najmanje jednim umetanjem ili izbacivanjem, naznačen time, da obuhvaća barem sljedeće korake:
Helmet (1) in particular work or sports protective helmet, comprising a structure (2) having: 
Kaciga (1) naročito radna ili sportska zaštitna kaciga, koja obuhvaća konstrukciju (2) koja sadrži: najmanje jednu uglavnom konveksnu vanjsku površinu (2a);
an amino acid sequence having at least 90% homology to amino acid residues 20 to 130 of SEQ ID NO: 32, 33 or 34. 
aminokiselinska sekvenca koja ima najmanje 90% homologije sa aminokiselinskim ostacima 20 do 130 iz sekv. id. br.: 32, 33 ili 34.
Further, the present invention relates to the binding molecule mentioned above, wherein the first and the second domain form a molecule that is selected from the group of (scFv)2, (single domain mAb)2, scFv-single domain mAb, diabody or oligomers thereof. 
Vezujuća molekula prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što prva i druga domena tvore molekulu koja je odabrana iz skupine koja sadrži (scFv),, (jedno domensko mAb),, scFv-jedno domensko mAb, diatijelo ili njihove oligomere.
may specifically be H or methyl, and R9 may specifically be: 
Rg može naročito biti H ili metil, a Ro može naročito biti: md
the modified protein encoding sequence encodes a protein that differs from a natural isolate by 10 amino acids or fewer, or 
se sekvenca koja kodira modificirani protein kodira protein koji razlikuje od prirodnog izolata za 10 aminokiselina ili manje, ili
The method according to claim 11, in which in said infectious diseases are caused by a bacterium, fungus, protozoon or virus. 
Primjena prema zahtjevu 19, kod koje je u spomenutim bolestima infektivna tvar bakterija, gljivica, protozoa ili virus.
formoterol, or a salt thereof or a solvate of said salt, at a dosage in the range of from 1 to 25 µg per actuation; a HFA propellant; a co-solvent; 
(b) formoterol ili njegovu sol ili solvat rečene soli u dozi u rasponu od 1 do 25 ug po aktiviranju; (c) -propelant HFA; (d) _kootapalo;
The dispenser of claims 1 to 7, wherein the dispenser is closed with a closure that prevents access to the container. 
Raspršivač sukladno bilo kojem prethodnom zahtjevu, pri čemu je raspršivač opremljen sredstvom (106) za zatvaranje radi sprječavanja pristupa u spremnik.
The mixture was cooled, diluted with water and extracted with EtOAc. 
Smjesa je hlađena, razrijeđena vodom i ekstrahirana sa FtOAc.
A method of treating a neurodegenerative disorder with a-synuclein pathology in an individual, or delaying onset of a neurodegenerative disorder with a-synuclein pathology in an individual at risk of developing the disorder, wherein the disorder with a-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites, comprising administering to the individual the monoclonal antibody or fragment thereof according to claim 1 . 
Upotreba protutijela, ili fragmenta, u skladu s bilo kojim od patentnih zahtjeva 1-8 ili pripravka u skladu s patentnim zahtjevom 9, namijenjena postavljanju dijagnoze in vitro ili praćenju razvoja neurodegenerativnog poremećaja s a-sinukleinskom patologijom, naznačena time što je za poremećaj s a-sinukleinskom patologijom karakteristično odlaganje Lewyjevih tijela i Lewyjevih neurita.
The modified virus of claim 1, wherein the virus is a DNA, RNA, double-stranded, or single-stranded virus. 
Oslabljeni virus prema zahtjevu 1., naznačen time što virus je DNK, RNK, dvolančani, ili jednolančani virus.
compound of the Formula m can be reacted with amino compound of Formula IV 
b) spoj s formulom III dalje može reagirati s amino spojem s formulom IV o
The method of claim 1, wherein the cumulative total amount of asparagine per unit volume in said medium is greater than 8 mM. 
Postupak prema Zahtjevu 1, naznačen time, što je kumulativna ukupna količina asparagina po jedinici volumena u spomenutom mediju veća od približno 8 mM.
enclosing a sealed capsule into a capsule enclosure space of a beverage production device by a relative displacement of at least two enclosing members which define the capsule enclosure space, 
- > zatvaranje nepropusno zatvorene čahure u prostor koji obuhvaća čahuru u uređaju za pripremanje napitka relativnim pomicanjem najmanje dva elementa za obuhvaćanje čahure (9, 13), koji elementi određuju prostor za obuhvaćanje čahure,
on different days and that a mean value is determined which is used as the inherent system value FA, from which the setpoint value AFA is calculated. 
u različitim danima 1 određuje se srednja vrijednost koja se koristi kao inherentna vrijednost sustava F,, od koje se izračunava zadana AF, vrijednost
A process for the preparation of a compound of formula (I) in the form of its Form I crystalline polymorph according to claim 3 comprising the step of crystallising a compound of formula (I) from methyl isobutyl ketone. 
Postupak pripreme spoja formule (I) u obliku kristalnog polimorfa njegovog Oblika I prema patentnom zahtjevu 3, naznačen time da sadrži korak kristalizacije spoja formule (1) iz metil izobutil ketona.
The watermark generator according to claim 2, wherein the synchronization inserter is configured to multiplicatively combine different time portions of the spread information representation, which different time portions represent different bits of the binary message data, with different synchronization spread sequences, such that the different synchronization spread sequences are combined with different bit spread sequences or with differently scaled versions of a given bit spread sequence. 
Generator vodenog žiga prema zahtjevu 2, naznačen time, da je uređaj za umetanje sinhronizacije konfiguriran za višestruko kombiniranje različitih vremenskih odsječaka od prikaza proširene informacije, gdje ti različiti vremenski odsječci predstavljaju različite bitove od binarnih podataka poruke, s različitim nizovima proširene sinhronizacije (a, b, c), tako da se različiti nizovi proširene sinhronizacije kombiniraju s različitim nizovima proširenog bita ili s različito odmjerenim verzijama danog niza proširenog bita.
hydroxyl protecting group such as a silyl protecting group, for example, TES 
hidroksilna zaštitna skupina kao što je silil zaštitna skupina, na primjer, TES P;
Preferably, the amount of brimonidine tartrate in the composition is about 0.1 to 0.6% (w/w). 
Kompozicija topičkog gela prema zahtjevu 5, pri čemu kompozicija sadrži: od 0,05 do 5% (w/w) brimonidina ili brimonidin tartrata.
An isolated antibody as claimed in claim 1 which has a heavy chain having the amino acid system set forth in SEQ ID NO:55 and a light chain having the amino acid sequence set forth in SEQ ID NO:18. 
Izolirano protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što ima teški lanac, čiji je aminokiselinski slijed iznijet u SEQ ID NO:55, te laki lanac, čiji je aminokiselinski slijed iznijet u SEQ ID NO:18.
The use according to any one of claims 1-4, wherein the medicament is suitable for oral administration. 
Pripravak prema patentnom zahtjevu 7 koji je pogodan za oralnu ili topičku primjenu.
The process according to claim 41 wherein 3-(3-fluorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide is prepared. 
Postupak u skladu s patentnim zahtjevom 41, gdje se dobiva amid 3-(3-fluorfenilsulfanil)-1#-pirolo[3,2-b] piridin-2-karboksilne kiseline.
A retroviral vector kit comprising: an integration-defective retroviral vector transfer cassette lacking a functional PPT; and a packaging cell line comprising at least one construct encoding one or more proteins proteins required for the retroviral vector to be packaged. 
Alat retrovirusnog vektora sadrži: (a) retrovirusnu vektorsku kazetu za prijenos manjkavu u integraciji kojoj nedostaje 3'-PPT; i (b) staničnu liniju za pakiranje koja sadrži najmanje jedan konstrukt koji kodira jedan ili više proteina potrebnih za pakiranje retrovirusnog vektora.
The treatment typically comprises the eradication of Helicobacter pylori in the subject. In some embodiments, the method of treatment comprises administering to said patient a therapeutically effective amount of a capsule comprising (1) an immediate release first dosage composition in the form of compressed minitablets, the immediate release first dosage composition comprising at least two antibiotics; and (2) a delayed release second dosage composition in the form of compressed minitablets, the delayed release second dosage composition comprising a proton pump inhibitor and a coating. 
(1) pripravak prve doze s trenutnim otpuštanjem u obliku komprimiranih minitableta, pripravak prve doze s trenutnim otpuštanjem koji se sastoji od najmanje dva antibiotika te (2) pripravak druge doze s odgođenim otpuštanjem u obliku komprimiranih minitableta, pripravak druge doze s odgođenim otpuštanjem koji se sastoji od inhibitora protonske pumpe i obloge, naznačen time što je, kada se testira u uređaju s košaricom, obloga pripravka druge doze s odgođenim otpuštanjem osmišljena tako da ispunjava kriterije profila otapanja u dvofaznom testu u uređaju s košaricom:
One of the above embodiments of the present invention relates to the 1-thio-D-glucitol compound of the formula I or IA where Ar1 is a phenylene group or a naphthylene group, or the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt. 
Spoj 1-tio-D-glucitol, ili njegova farmaceutski prihvatljiva sol, ili hidrat spoja ili njegova sol prema zahtjevu 1 ili 2, naznačen time da Ar je fenilen skupina ili naftilen skupina.
The method of claim 1, wherein the cumulative total amount of riboflavin per unit volume in said medium is greater than 2.0 mg/L. 
Postupak prema Zahtjevu 1, naznačen time, što je kumulativna ukupna količina riboflavina po jedinici volumena u spomenutom mediju veća od približno 2,0 mg/L.
The anti-FOLR1 antibody or anti-FOLR1 immunoconjugate for use of claim 1, wherein the IHC is performed manually or using an automated system. 
Protutijelo protiv FOLR1 ili imunokonjugat protiv FOLR1, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što se IHC provodi ručno ili automatiziranim sustavom.
Vector according to claim 9, characterised in that said vector further comprises promoter operably linked to said nucleic acid molecule. 
Vektor prema zahtjevu 8, naznačen time, da navedeni vektor nadalje obuhvaća promotor koji je radno povezan sa spomenutom molekulom nukleinske kiseline.
an aqueous dispersion containing as the adhesive polymer: butyl acrylate/2-ethylhexyl acrylate/vinyl acetate terpolymer, an aqueous dispersion containing as the adhesive polymer a crosslinked acrylic acid polymer with isocyanate at a concentration of 2% by weight of the total weight of said wet adhesive composition. 
Cc) otopina na bazi stiren-butadien kopolimera u organskom otapalu, d) vodenih disperzija na bazi terpolimera (butil akrilata/2-etilheksil akrilata/vinil acetata), e) vodenih disperzija umreženog akrilnog kiselog polimera s izocijanatom u omjeru od 2% prema težini u ukupnoj težini mokrog adhezivnog sastava,
Thus the pressurizing fluid may be a liquid or a gas, whichever is available. 
Tako, dakle, tlačni medij može biti tekućina ili plin, što god je dostupno.
(xiii) a light chain variable region amino acid sequence encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOS:136-138; and 
Izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1, naznačeno time da sadrži varijabilnu regiju lakog lanca aminokiselinske sekvence kodirane od strane nukleotidne sekvence izabrane od grupe koja se sastoji od SEQ ID
The process of clause 6, wherein the ether solvent that has low miscibility with water is selected from the group consisting of tert -butyl methyl ether, tert -butyl ethyl ether, tert- amyl methyl ether, isopropyl ether, and mixtures thereof. 
Postupak prema patentnom zahtjevu 5, gdje je etersko otapalo koji ima nisku mješavost sa vodom izabrano iz grupe koju čine terc-butil metil eter, terc-butil etil eter, terc-amil metil eter, izopropil eter i njihove smjese.
The solid composition for use according to claim 1 or 2, wherein said methylene blue is methylene blue anhydrous or hydrate. 
Čvrsti pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedeno metilensko modrilo metilensko modrilo bezvodno ili u obliku hidrata.
The compound of Formula XLII can be hydrogenated to form a compound of Formula XLIII which can then be reduced to form a compound of Formula XLIV. 
*OR" doma Oo Formula XLII! c. redukciju spoja Formule XLIII, čime se dobiva spoj Formule XLIV:
Use according to claim 15 wherein the protein-containing fermentation agent comprises yeast. 
Uporaba prema zahtjevu 15 naznačena time da fermentacijsko sredstvo koje sadrži proteine sadrži kvasac.
said thermochromic ink is coloured below said predetermined temperature and becomes colourless when said predetermined temperature is reached or exceeded; 
navedena termokromna tiskarska boja ima obojenje ispod spomenute predodređene temperature i postaje bezbojna kada se dosegne ili premaši spomenuta predodređena temperatura;
wherein n is an integer from 0 to 20, and n1 is an integer from 1 to 20; 
[image] gdje je n cijeli broj od 0 do 20, a n1 jest cijeli broj od 1 do 20,
A pharmaceutical composition for treatment of cancer, the pharmaceutical composition having properties of an androgen receptor antagonist, comprising a therapeutically effective amount of a compound that is an (R)-stereoisomer of a substituted 2-thioxo-imidazolidine-4-one having a structure according to general formula 1, 
Farmaceutska kompozicija za primjenu u liječenju raka koja ima svojstva antagoniste androgenih receptora i sadrži efikasnu količinu spojeva koji su prikazani formulom 1 prema patentnom zahtjevu 1 i inertni punilac ili otapalo.